BioSpace News Archive

Business

Adynxx Reports Third Quarter 2019 Financial Results

Adynxx, Inc. announced financial results and provided a business update for the quarter ended September 30, 2019.

November 14, 2019
·
8 min read
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

Sustained innovation beyond 2024 based on a promising early stage pipeline and novel research platforms intended to provide transformative benefit for targeted populations with high unmet needs

November 14, 2019
·
6 min read
Policy

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Axonics Modulation Technologies, Inc. announced the approval of the Axonics r-SNM® System by the United States Food & Drug Administration for the clinical indications of overactive bladder and urinary retention.

November 14, 2019
·
6 min read
Business

MediWound Reports Third Quarter 2019 Financial Results

Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020

November 14, 2019
·
12 min read
Business

Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019

Results Highlighted by 33% Increase in Revenues for Guardion’s Flagship Medical Food Lumega-Z®

November 14, 2019
·
12 min read
Deals

CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

CURE Pharmaceutical announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505 pharmaceutical products.

November 14, 2019
·
4 min read
Deals

Bruker Announces Quarterly Dividend - Nov. 14, 2019

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

November 14, 2019
·
1 min read
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology

Key Opinion Leaders Will Provide Updated Results on Efficacy, Safety and Delivery of MDNA55

November 14, 2019
·
2 min read
Genetown

Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference

Seres Therapeutics, Inc. announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET.

November 14, 2019
·
1 min read
Policy

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa

Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy

November 14, 2019
·
9 min read